Skip to NavigationSkip to content


Over half of all US/EU regulator warnings issued to Indian and Chinese manufacturers, report finds

Concerns have been raised concerning the integrity of the global supply chain after a report from The Pharmaceutical Journal revealed that over half of the total formal warnings issued by US and European regulatory bodies are directed at facilities based in India or China.

The data noted by the report show that, of the 75 warning letters published to manufacturers by the FDA’s Office of Manufacturing Quality between early 2018 and August 2019, 37 in total were sent to these two countries – 18 to China and 19 to India.

Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world

Published on 22/07/19 at 10:25am

The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been sacrificed in the pursuit of bottom level prices. Louis Goss talks to investigative journalist Katherine Eban as she discusses the realities of the generic drug industry today.

GSK opens new manufacturing plants in Singapore

British multinational GlaxoSmithKline has opened two new manufacturing plants in Singapore.

The UK firm has also expanded facilities at its Jurong site, as part of an effort to “accelerate the supply of new breakthrough medicines to patients globally.”

The $96 million investment will see GSK employ a process called ‘continuous manufacturing’ with the aim of reducing production time and thus enabling faster supply of medicines across the globe.

Contract manufacturing services industry set to grow at CAGR of 10.6% between 2017-2027

The biopharmaceutical contract manufacturing market is expected to grow at a compound annual growth rate (CAGR) of 10.6% between 2017 and 2027, according to a report from Future Market Insights (FMI).

While Europe will continue to be the main source market for biopharmaceutical contract manufacturing services, the North American market is expected to expand at a CAGR close to 10% as profit margins remain higher in Europe than in the United States.

Three workers killed by explosion at pharma factory in India

Image Credit:

Three engineers have been killed in an explosion at a manufacturing facility in India.

Two Chinese engineers and one Indian engineer died after a boiler exploded at the Pusilin Biotechnology Private Limited facilities in the Indian state of Haryana.

The explosion happened as the three workers tried to fix the boiler at the facilities in Haryana close to New Delhi. All three workers died instantly, according to CGTN.

The news comes just weeks after ten workers were killed in an explosion in the city of Jinan.

Avara Avlon falls into administration putting 270 Bristol jobs at risk

Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at risk.

The contract development and manufacturing organisation (CDMO) is hoping to sell facilities in Avonmouth a suburb of Bristol, which it bought from AstraZeneca in 2016.

Irish Pfizer employees to launch industrial action ballot over pensions scheme

Pfizer employees have rejected a Labour Court recommendation regarding their pension scheme, opting to initiate a ballot over potential industrial action instead.

As many as 900 workers at Pfizer’s operations in Ireland will take part in the ballot which will determine what happens next.

The decision comes after Pfizer sought to switch 900 of its employees from pension schemes that offer workers a proportion of their salary on retirement to a new plan which would not offer this guarantee.  

Boehringer expands manufacturing facility in Shanghai

German firm Boehringer Ingelheim has expanded the capacity of its commercial manufacturing site for biologics in Shanghai, China.

The expansion will see the installation of an additional bioreactor into the company’s OASIS Shanghai facility.

“We are fully committed to our biopharmaceutical contract manufacturing business in China and it is our utmost goal to serve our customers and their patients with high quality medicines in China and in the global market’, said Prof Buecheler, Head of Biopharmaceutical Business Unit at Boehringer Ingelheim.

Sun Pharma's New Jersey manufacturing overhaul puts 96 jobs at risk

Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to “improve cost efficiencies, it has emerged – a move which puts almost 100 jobs at risk.

Specifically, the company plans to relocate operations at its facility in Cranbury to its site in New Brunswick, which will threaten 96 positions. The firm’s intention was confirmed in a WARN notice published by the New Jersey Department of Labor and Workforce Development

GSK veteran Dave Tudor joins MMIC in Scotland

Published on: 09/11/18

GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), a new manufacturing centre designed to increase the speed and cost effectiveness of the process through which medicines are brought to market. The facility is set to be built in Renfrewshire, Scotland over the next two years.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches